

## [Bleomycin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01DC01](#)

EMLc

Indication

Kaposi sarcoma of unspecified primary site ICD11 code: [2C27.Z](#)

INN

Bleomycin

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > unspecified:** 15000 IU in vial (as sulfate)

EML status history

First added in 1979 ([TRS 641](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Bleomycin](#)

[DrugBank](#)

[Bleomycin](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the strength of bleomycin powder for injection be expressed in IU and not mg, to reflect dosing protocols.